DE60325725D1 - Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs - Google Patents

Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs

Info

Publication number
DE60325725D1
DE60325725D1 DE60325725T DE60325725T DE60325725D1 DE 60325725 D1 DE60325725 D1 DE 60325725D1 DE 60325725 T DE60325725 T DE 60325725T DE 60325725 T DE60325725 T DE 60325725T DE 60325725 D1 DE60325725 D1 DE 60325725D1
Authority
DE
Germany
Prior art keywords
mab
monoclonal antibody
diagnosis
optionally
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60325725T
Other languages
German (de)
English (en)
Inventor
Claude Prigent
Anne Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANG BRETAGNE ETS FRANC
Centre National de la Recherche Scientifique CNRS
Etablissement Francais du Sang
Original Assignee
SANG BRETAGNE ETS FRANC
Centre National de la Recherche Scientifique CNRS
Etablissement Francais du Sang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SANG BRETAGNE ETS FRANC, Centre National de la Recherche Scientifique CNRS, Etablissement Francais du Sang filed Critical SANG BRETAGNE ETS FRANC
Application granted granted Critical
Publication of DE60325725D1 publication Critical patent/DE60325725D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
DE60325725T 2002-06-12 2003-06-12 Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs Expired - Lifetime DE60325725D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0207212A FR2840905B1 (fr) 2002-06-12 2002-06-12 Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers
PCT/FR2003/001772 WO2003106500A1 (fr) 2002-06-12 2003-06-12 Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers

Publications (1)

Publication Number Publication Date
DE60325725D1 true DE60325725D1 (de) 2009-02-26

Family

ID=29595167

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60325725T Expired - Lifetime DE60325725D1 (de) 2002-06-12 2003-06-12 Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs

Country Status (9)

Country Link
US (1) US7514231B2 (enExample)
EP (1) EP1511771B1 (enExample)
JP (1) JP4555681B2 (enExample)
AT (1) ATE420115T1 (enExample)
AU (1) AU2003255671A1 (enExample)
CA (1) CA2489214C (enExample)
DE (1) DE60325725D1 (enExample)
FR (1) FR2840905B1 (enExample)
WO (1) WO2003106500A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
EP1778669A2 (en) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2239692C (en) * 1995-12-18 2008-12-16 Sugen, Inc. Diagnosis and treatment of aur-1 and/or aur-2 related disorders

Also Published As

Publication number Publication date
WO2003106500A1 (fr) 2003-12-24
EP1511771B1 (fr) 2009-01-07
ATE420115T1 (de) 2009-01-15
CA2489214C (fr) 2013-08-06
CA2489214A1 (fr) 2003-12-24
EP1511771A1 (fr) 2005-03-09
US20070117163A1 (en) 2007-05-24
JP4555681B2 (ja) 2010-10-06
FR2840905B1 (fr) 2006-07-07
FR2840905A1 (fr) 2003-12-19
AU2003255671A1 (en) 2003-12-31
US7514231B2 (en) 2009-04-07
JP2006513135A (ja) 2006-04-20
AU2003255671A8 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
Knittel et al. Localization of liver myofibroblasts and hepatic stellate cells in normal and diseased rat livers: distinct roles of (myo-) fibroblast subpopulations in hepatic tissue repair
Pouliliou et al. Gamma histone 2AX (γ-H2AX) as a predictive tool in radiation oncology
ATE538809T1 (de) Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff
RU2007139912A (ru) Способ прогнозирования течения рака на основе количественного анализа клеточного рецептора витамина фолата
JP2009525478A5 (enExample)
WO2005084109A3 (en) Cancer specific gene mh15
ATE230487T1 (de) Verfahren zur frühen diagnose von carcinomen
EP2444505A3 (en) Urine markers for detection of bladder cancer
DE60239059D1 (de) Verfahren und zusammensetzungen zur hemmung, prävention oder verringerung des tumorzellwachstums beingen einer antiöstrogen-therapie resistent sind
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
RU2007141067A (ru) Терапия с помощью антител к egfr, основанная на повышенном числе копий гена egfr в опухолевых тканях
WO2014197937A1 (en) Methods for detecting prostate cancer
ATE447715T1 (de) Automatische glykofingerabdruck-strategie
Larsen et al. Functional and phenotypical comparison of myofibroblasts derived from biopsies and bronchoalveolar lavage in mild asthma and scleroderma
CN1928563A (zh) 乳腺癌的免疫组化诊断试剂盒和测试片
van Beijnum et al. Spatial transcriptomics reveals asymmetric cellular responses to injury in the regenerating spiny mouse (Acomys) ear
ATE459883T1 (de) Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
DE60325725D1 (de) Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs
RU2013104137A (ru) Изоформы bard1 при раке легкого и колоректальном раке и их применение
IL190401A0 (en) Antibodies against april as biomarkers for early prognosis of lymphoma patients
FR2919061B1 (fr) Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
WO2004040312A3 (fr) Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
WO2003068268A3 (en) Treatment, diagnosis and imaging of disease
DE50313393D1 (de) Verfahren zur diagnose von entzündungserkrankungen und infektionen mittels bestimmung von lasp-1/ lap-1
WO2024252184A3 (en) Anti-cldn18_2 antibody and an in vitro diagnostic kit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition